[Hospital diabetes management (Update 2023)].

Diabetesmanagement im Krankenhaus (Update 2023).
Humans Diabetes Mellitus / diagnosis Hypoglycemic Agents / therapeutic use Insulin / therapeutic use Blood Glucose Hospitals Diabetes Mellitus, Type 2 / diagnosis
Adults with diabetes mellitus General ward Hospital diabetes management Insulin Oral antihyperglycemic drugs Therapy

Journal

Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R

Informations de publication

Date de publication:
Jan 2023
Historique:
accepted: 22 02 2023
medline: 28 4 2023
pubmed: 27 4 2023
entrez: 26 4 2023
Statut: ppublish

Résumé

This position statement presents the recommendations of the Austrian Diabetes Association for diabetes management of adult patients during inpatient stay. It is based on the current evidence with respect to blood glucose targets, insulin therapy and treatment with oral/injectable antidiabetic drugs during inpatient hospitalization. Additionally, special circumstances such as intravenous insulin therapy, concomitant therapy with glucocorticoids and use of diabetes technology during hospitalization are discussed. Dieses Positionspapier beinhaltet die Empfehlungen der Österreichischen Diabetes Gesellschaft zum Management von erwachsenen Patient:innen mit Diabetes mellitus während stationärer Aufenthalte und basiert auf aktueller Evidenz zu Blutglukosezielbereichen, Insulintherapie und Therapie mit oralen/injizierbaren Antidiabetika während stationärer Aufenthalte. Zusätzlich werden Spezialsituationen wie intravenöse Insulintherapie, begleitende Steroidtherapie sowie die Anwendung von Diabetestechnologie im stationären Bereich diskutiert.

Autres résumés

Type: Publisher (ger)
Dieses Positionspapier beinhaltet die Empfehlungen der Österreichischen Diabetes Gesellschaft zum Management von erwachsenen Patient:innen mit Diabetes mellitus während stationärer Aufenthalte und basiert auf aktueller Evidenz zu Blutglukosezielbereichen, Insulintherapie und Therapie mit oralen/injizierbaren Antidiabetika während stationärer Aufenthalte. Zusätzlich werden Spezialsituationen wie intravenöse Insulintherapie, begleitende Steroidtherapie sowie die Anwendung von Diabetestechnologie im stationären Bereich diskutiert.

Identifiants

DOI: 10.1007/s00508-023-02177-5 PMID: 37101046 PMC: PMC10133359
pubmed: 37101046
doi: 10.1007/s00508-023-02177-5
pii: 10.1007/s00508-023-02177-5
pmc: PMC10133359
doi:

Substances chimiques

Hypoglycemic Agents 0
Insulin 0
Blood Glucose 0

Types de publication

English Abstract Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

242-255

Informations de copyright

© 2023. The Author(s).

Références

Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009;373(9677):1798–807.
pubmed: 19465235 pmcid: 3144755 doi: 10.1016/S0140-6736(09)60553-5
Kamel HK, Rodriguez-Saldana J, Flaherty JH, Miller DK. Diabetes mellitus among ethnic seniors: contrasts with diabetes in whites. Clin Geriatr Med. 1999;15(2):265–78.
pubmed: 10339633 doi: 10.1016/S0749-0690(18)30059-4
Morley JE. An overview of diabetes mellitus in older persons. Clin Geriatr Med. 1999;15(2):211–24.
pubmed: 10339629 doi: 10.1016/S0749-0690(18)30055-7
Carpenter DL, Gregg SR, Xu K, Buchman TG, Coopersmith CM. Prevalence and impact of unknown diabetes in the ICU. Crit Care Med. 2015;43(12):e541–e50.
pubmed: 26465219 doi: 10.1097/CCM.0000000000001353
Swanson CM, Potter DJ, Kongable GL, Cook CB. Update on inpatient glycemic control in hospitals in the United States. Endocr Pract. 2011;17(6):853–61.
pubmed: 21550947 doi: 10.4158/EP11042.OR
McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28(4):810–5.
pubmed: 15793178 doi: 10.2337/diacare.28.4.810
Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care. 2010;33(8):1783–8.
pubmed: 20435798 pmcid: 2909062 doi: 10.2337/dc10-0304
Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 2003;78(12):1471–8.
pubmed: 14661676 doi: 10.4065/78.12.1471
Falciglia M, Freyberg RW, Almenoff PL, D’Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med. 2009;37(12):3001–9.
pubmed: 19661802 pmcid: 2905804 doi: 10.1097/CCM.0b013e3181b083f7
Bruno A, Gregori D, Caropreso A, Lazzarato F, Petrinco M, Pagano E. Normal glucose values are associated with a lower risk of mortality in hospitalized patients. Diabetes Care. 2008;31(11):2209–10.
pubmed: 18716050 pmcid: 2571047 doi: 10.2337/dc08-0672
Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Barnighausen T, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423–30.
pubmed: 28456416 doi: 10.1016/S2213-8587(17)30097-9
Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.
pubmed: 20969750 pmcid: 2984379 doi: 10.1186/1478-7954-8-29
Aro S, Kangas T, Reunanen A, Salinto M, Koivisto V. Hospital use among diabetic patients and the general population. Diabetes Care. 1994;17(11):1320–9.
pubmed: 7821174 doi: 10.2337/diacare.17.11.1320
Donnan PT, Leese GP, Morris AD, Diabetes A. Research in Tayside SMMUC. Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland: a retrospective cohort study of resource use. Diabetes Care. 2000;23(12):1774–9.
pubmed: 11128351 doi: 10.2337/diacare.23.12.1774
Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87(3):978–82.
pubmed: 11889147 doi: 10.1210/jcem.87.3.8341
McCoy RG, Herrin J, Lipska KJ, Shah ND. Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. J Diabetes Complications. 2018;32(7):693–701.
pubmed: 29751961 pmcid: 6015781 doi: 10.1016/j.jdiacomp.2018.04.007
McCoy RG, Lipska KJ, Herrin J, Jeffery MM, Krumholz HM, Shah ND. Hospital readmissions among commercially insured and medicare advantage beneficiaries with diabetes and the impact of severe hypoglycemic and hyperglycemic events. J Gen Intern Med. 2017;32(10):1097–105.
pubmed: 28685482 pmcid: 5602759 doi: 10.1007/s11606-017-4095-x
Lombardo F, Maggini M, Gruden G, Bruno G. Temporal trend in hospitalizations for acute diabetic complications: a nationwide study, Italy, 2001–2010. PLoS ONE. 2013;8(5):e63675.
pubmed: 23717464 pmcid: 3662780 doi: 10.1371/journal.pone.0063675
Australian N‑SSIft, New Zealand Intensive Care Society Clinical Trials G, Canadian Critical Care Trials G, Finfer S, Chittock D, Li Y, et al. Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study. Intensive Care Med. 2015;41(6):1037–47.
doi: 10.1007/s00134-015-3757-6
American Diabetes A. 14. Diabetes care in the hospital: Standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S144–S51.
doi: 10.2337/dc18-S014
International Hypoglycaemia Study G. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40(1):155–7.
doi: 10.2337/dc16-2215
Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31.
pubmed: 19429873 pmcid: 2681039 doi: 10.2337/dc09-9029
Kufeldt J, Kovarova M, Adolph M, Staiger H, Bamberg M, Haring HU, et al. Prevalence and distribution of diabetes mellitus in a maximum care hospital: urgent need for HbA
pubmed: 28750430 doi: 10.1055/s-0043-112653
Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38.
pubmed: 22223765 doi: 10.1210/jc.2011-2098
Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009;15(4):353–69.
pubmed: 19454396 doi: 10.4158/EP09102.RA
King AB, Armstrong DU. Basal bolus dosing: a clinical experience. Curr Diabetes Rev. 2005;1(2):215–20.
pubmed: 18220597 doi: 10.2174/1573399054022794
Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, et al. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(2):564–9.
pubmed: 19017758 doi: 10.1210/jc.2008-1441
Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553–91.
pubmed: 14747243 doi: 10.2337/diacare.27.2.553
Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181–6.
pubmed: 17513708 doi: 10.2337/dc07-0295
Rubin DJ, Rybin D, Doros G, McDonnell ME. Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. Diabetes Care. 2011;34(8):1723–8.
pubmed: 21700919 pmcid: 3142056 doi: 10.2337/dc10-2434
Hochfellner DA, Rainer R, Ziko H, Aberer F, Simic A, Lichtenegger KM, Beck P, Donsa K, Pieber TR, Fruhwald FM, Rosenkranz AR, Kamolz LP, Baumann PM, Mader JK, Plank J. Efficient and safe glycaemic control with basal-bolus insulin therapy during fasting periods in hospitalized patients with type 2 diabetes using decision support technology: A post hoc analysis. Diabetes Obes Metab. 2021; 23(9):2161–9. https://doi.org/10.1111/dom.14458 .
doi: 10.1111/dom.14458 pubmed: 34081386
George S, Dale J, Stanisstreet D. A guideline for the use of variable rate intravenous insulin infusion in medical inpatients. Diabet Med. 2015;32(6):706–13.
pubmed: 25980646 doi: 10.1111/dme.12756
Juneja R, Roudebush C, Kumar N, Macy A, Golas A, Wall D, et al. Utilization of a computerized intravenous insulin infusion program to control blood glucose in the intensive care unit. Diabetes Technol Ther. 2007;9(3):232–40.
pubmed: 17561793 doi: 10.1089/dia.2006.0015
American Diabetes Association. Erratum. Diabetes Care in the Hospital. Sec. 14. In Standards of medical care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1);S120–S127. Diabetes Care. 2017;40(7):986.
pmcid: 5481990
Van den Berghe G, Wilmer A, Milants I, Wouters PJ, Bouckaert B, Bruyninckx F, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes. 2006;55(11):3151–9.
pubmed: 17065355 doi: 10.2337/db06-0855
Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003;125(5):1007–21.
pubmed: 12771873 doi: 10.1067/mtc.2003.181
Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999;67(2):352–60. discussion 60–2.
pubmed: 10197653 doi: 10.1016/S0003-4975(99)00014-4
van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–67.
pubmed: 11794168 doi: 10.1056/NEJMoa011300
Goldberg PA, Siegel MD, Sherwin RS, Halickman JI, Lee M, Bailey VA, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care. 2004;27(2):461–7.
pubmed: 14747229 doi: 10.2337/diacare.27.2.461
Mendez CE, Umpierrez GE. Management of type 1 Diabetes in the hospital setting. Curr Diab Rep. 2017;17(10):98.
pubmed: 28913745 doi: 10.1007/s11892-017-0919-7
Perez A, Ramos A, Carreras G. Insulin therapy in hospitalized patients. Am J Ther. 2020;27(1):e71–e8.
pubmed: 31833876 doi: 10.1097/MJT.0000000000001078
Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O’Brien PC, et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med. 2007;146(4):233–43.
pubmed: 17310047 doi: 10.7326/0003-4819-146-4-200702200-00002
Smith I, Kranke P, Murat I, Smith A, O’Sullivan G, Soreide E, et al. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2011;28(8):556–69.
pubmed: 21712716 doi: 10.1097/EJA.0b013e3283495ba1
Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006;355(18):1903–11.
pubmed: 17079764 doi: 10.1056/NEJMcp060094
Trence DL, Kelly JL, Hirsch IB. The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab. 2003;88(6):2430–7.
pubmed: 12788838 doi: 10.1210/jc.2003-030347
Umpierrez GE, Pasquel FJ. Management of inpatient hyperglycemia and Diabetes in older adults. Diabetes Care. 2017;40(4):509–17.
pubmed: 28325798 pmcid: 5864102 doi: 10.2337/dc16-0989
Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21(12):2527–41.
pubmed: 21866433 doi: 10.1007/s00330-011-2225-0
Deutsche Diabetesgesellschaft. Positionspapier der Deutschen Diabetes Gesellschaft zur Therapie des Diabetes mellitus im Krankenhaus. 2018.
Perkovic V, Agarwal R, Fioretto P, Hemmelgarn BR, Levin A, Thomas MC, et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90(6):1175–83.
pubmed: 27884312 doi: 10.1016/j.kint.2016.09.010
Lalau JD, Kajbaf F, Protti A, Christensen MM, De Broe ME, Wiernsperger N. Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm. Diabetes Obes Metab. 2017;19(11):1502–12.
pubmed: 28417525 doi: 10.1111/dom.12974
Luft D, Deichsel G, Schmulling RM, Stein W, Eggstein M. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol. 1983;80(4):484–9.
pubmed: 6624712 doi: 10.1093/ajcp/80.4.484
Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy. 2012;32(7):613–7.
pubmed: 22570146 doi: 10.1002/j.1875-9114.2011.01088.x
Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5(2):125–33.
pubmed: 27964837 doi: 10.1016/S2213-8587(16)30402-8
Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36(11):3430–5.
pubmed: 23877988 pmcid: 3816910 doi: 10.2337/dc13-0277
US Food and Drug Association. FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin 2016. 2016. http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm . Zugegriffen: 8. Aug. 2018.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
pubmed: 27633186 doi: 10.1056/NEJMoa1607141
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
pubmed: 27295427 pmcid: 4985288 doi: 10.1056/NEJMoa1603827
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr., Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.
pubmed: 30291013 doi: 10.1016/S0140-6736(18)32261-X
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
pubmed: 31189511 doi: 10.1016/S0140-6736(19)31149-3
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
pubmed: 26378978 doi: 10.1056/NEJMoa1504720
Umpierrez G, Korytkowski M. Diabetic emergencies—Ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12(4):222–32.
pubmed: 26893262 doi: 10.1038/nrendo.2016.15
van Raalte DH, Diamant M. Steroid diabetes: from mechanism to treatment? Neth J Med. 2014;72(2):62–72.
pubmed: 24659588
Tamez-Perez HE, Quintanilla-Flores DL, Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Tamez-Pena AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 2015;6(8):1073–81.
pubmed: 26240704 pmcid: 4515447 doi: 10.4239/wjd.v6.i8.1073
Katsuyama T, Sada KE, Namba S, Watanabe H, Katsuyama E, Yamanari T, et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2015;108(2):273–9.
pubmed: 25765669 doi: 10.1016/j.diabres.2015.02.010
Stauber MN, Aberer F, Oulhaj A, Mader JK, Zebisch A, Pieber TR, et al. Early hyperglycemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease. Biol Blood Marrow Transplant. 2017; 23(7):1186–92. https://doi.org/10.1016/j.bbmt.2017.03.010 .
doi: 10.1016/j.bbmt.2017.03.010 pubmed: 28285080
Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006;69(3):588–95.
pubmed: 16395250 doi: 10.1038/sj.ki.5000116
Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15(5):469–74.
pubmed: 19454391 doi: 10.4158/EP08331.RAR
Peters AL, Ahmann AJ, Hirsch IB, Raymond JK. Advances in glucose monitoring and automated insulin delivery: supplement to Endocrine Society clinical practice guidelines. J Endocr Soc. 2018;2(11):1214–25.
pubmed: 30324178 pmcid: 6179160 doi: 10.1210/js.2018-00262
American Diabetes Association, et al. 7. Diabetes technology: Standards of medical care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S97–S112.
doi: 10.2337/dc22-S007
Thompson B, Korytkowski M, Klonoff DC, Cook CB. Consensus statement on use of continuous subcutaneous insulin infusion therapy in the hospital. J Diabetes Sci Technol. 2018;12(4):880–9.
pubmed: 29681173 pmcid: 6134295 doi: 10.1177/1932296818769933
Cook CB, Beer KA, Seifert KM, Boyle ME, Mackey PA, Castro JC. Transitioning insulin pump therapy from the outpatient to the inpatient setting: a review of 6 years’ experience with 253 cases. J Diabetes Sci Technol. 2012;6(5):995–1002.
pubmed: 23063024 pmcid: 3570832 doi: 10.1177/193229681200600502
Cook CB, McNaughton DA, Braddy CM, Jameson KA, Roust LR, Smith SA, et al. Management of inpatient hyperglycemia: assessing perceptions and barriers to care among resident physicians. Endocr Pract. 2007;13(2):117–24.
pubmed: 17490924 doi: 10.4158/EP.13.2.117
Noschese ML, DiNardo MM, Donihi AC, Gibson JM, Koerbel GL, Saul M, et al. Patient outcomes after implementation of a protocol for inpatient insulin pump therapy. Endocr Pract. 2009;15(5):415–24.
pubmed: 19491071 doi: 10.4158/EP09063.ORR
Houlden RL, Moore S. In-hospital management of adults using insulin pump therapy. Can J Diabetes. 2014;38(2):126–33.
pubmed: 24690507 doi: 10.1016/j.jcjd.2014.01.011
Kannan S, Satra A, Calogeras E, Lock P, Lansang MC. Insulin pump patient characteristics and glucose control in the hospitalized setting. J Diabetes Sci Technol. 2014;8(3):473–8.
pubmed: 24876608 pmcid: 4455446 doi: 10.1177/1932296814522809
Grunberger G, Bailey TS, Cohen AJ, Flood TM, Handelsman Y, Hellman R, et al. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract. 2010;16(5):746–62.
pubmed: 21356638 doi: 10.4158/EP.16.5.746
Thompson B, Leighton M, Korytkowski M, Cook CB. An overview of safety issues on use of insulin pumps and continuous glucose monitoring systems in the hospital. Curr Diab Rep. 2018;18(10):81.
pubmed: 30120619 doi: 10.1007/s11892-018-1056-7
Yeh T, Yeung M, Mendelsohn Curanaj FA. Managing patients with insulin pumps and continuous glucose monitors in the hospital: to wear or not to wear. Curr Diab Rep. 2021;21(2):7.
pubmed: 33449214 pmcid: 7810103 doi: 10.1007/s11892-021-01375-7
Umpierrez GE, Klonoff DC. Diabetes technology update: use of insulin pumps and continuous glucose monitoring in the hospital. Diabetes Care. 2018;41(8):1579–89.
pubmed: 29936424 pmcid: 6054505 doi: 10.2337/dci18-0002
Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, et al. Continuous glucose monitoring: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(10):2968–79.
pubmed: 21976745 doi: 10.1210/jc.2010-2756
Lansang MC, Modic MB, Sauvey R, Lock P, Ross D, Combs P, et al. Approach to the adult hospitalized patient on an insulin pump. J Hosp Med. 2013;8(12):721–7.
pubmed: 24227761 doi: 10.1002/jhm.2109
Tellez SE, Hornung LN, Courter JD, Abu-El-Haija M, Nathan JD, Lawson SA, et al. Inaccurate glucose sensor values after hydroxyurea administration. Diabetes Technol Ther. 2021;23(6):443–51.
pubmed: 33314990 pmcid: 8881951 doi: 10.1089/dia.2020.0490
Nair BG, Dellinger EP, Flum DR, Rooke GA, Hirsch IB. A pilot study of the feasibility and accuracy of inpatient continuous glucose monitoring. Diabetes Care. 2020;43(11):e168–e9.
pubmed: 32393587 doi: 10.2337/dc20-0670
Schaupp L, Donsa K, Neubauer KM, Mader JK, Aberer F, Holl B, et al. Taking a closer look—Continuous glucose monitoring in non-critically ill hospitalized patients with type 2 diabetes mellitus under basal-bolus insulin therapy. Diabetes Technol Ther. 2015;17(9):611–8.
pubmed: 25927357 doi: 10.1089/dia.2014.0343
Galindo RJ, Migdal AL, Davis GM, Urrutia MA, Albury B, Zambrano C, et al. Comparison of the freestyle libre pro flash Continuous Glucose Monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen. Diabetes Care. 2020;43(11):2730–5.
pubmed: 32641372 pmcid: 7809713 doi: 10.2337/dc19-2073
Fortmann AL, Spierling Bagsic SR, Talavera L, Garcia IM, Sandoval H, Hottinger A, et al. Glucose as the fifth vital sign: A randomized controlled trial of continuous glucose monitoring in a non-ICU hospital setting. Diabetes Care. 2020;43(11):2873–7.
pubmed: 32855160 pmcid: 7576427 doi: 10.2337/dc20-1016
Dillmann C, Amoura L, Fall Mostaine F, Coste A, Bounyar L, Kessler L. Feasibility of real-time continuous glucose monitoring telemetry system in an inpatient diabetes unit: a pilot study. J Diabetes Sci Technol. 2022;16(4):955–61.
pubmed: 33660531 doi: 10.1177/1932296821994586
Singh LG, Satyarengga M, Marcano I, Scott WH, Pinault LF, Feng Z, et al. Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: the glucose telemetry system, a randomized clinical trial. Diabetes Care. 2020;43(11):2736–43.
pubmed: 32759361 pmcid: 7576426 doi: 10.2337/dc20-0840
Galindo RJ, Umpierrez GE, Rushakoff RJ, Basu A, Lohnes S, Nichols JH, et al. Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline. J Diabetes Sci Technol. 2020;14(6):1035–64.
pubmed: 32985262 pmcid: 7645140 doi: 10.1177/1932296820954163
Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, et al. Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med. 2018; https://doi.org/10.1056/nejmoa1805233 .
doi: 10.1056/nejmoa1805233 pubmed: 30428293
Thabit H, Hartnell S, Allen JM, Lake A, Wilinska ME, Ruan Y, et al. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. 2017;5(2):117–24.
pubmed: 27836235 doi: 10.1016/S2213-8587(16)30280-7
Neubauer KM, Schaupp L, Plank J, Augustin T, Mautner SI, Tschapeller B, et al. Failure to control hyperglycemia in noncritically ill diabetes patients despite standard glycemic management in a hospital setting. J Diabetes Sci Technol. 2013;7(2):402–9.
pubmed: 23566999 pmcid: 3737642 doi: 10.1177/193229681300700217
Hochfellner DA, Rainer R, Ziko H, Aberer F, Simic A, Lichtenegger KM, et al. Efficient and safe glycaemic control with basal-bolus insulin therapy during fasting periods in hospitalized patients with type 2 diabetes using decision support technology: A post hoc analysis. Diabetes Obes Metab. 2021;23(9):2161–9.
pubmed: 34081386 doi: 10.1111/dom.14458
Spat S, Donsa K, Beck P, Höll B, Mader JK, Schaupp L, et al. A mobile computerized decision support system to prevent hypoglycemia in hospitalized patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2017;11(1):20–8.
pubmed: 27810995 doi: 10.1177/1932296816676501
Neubauer KM, Mader JK, Höll B, Aberer F, Donsa K, Augustin T, et al. Standardized glycemic management with a computerized Workflow and decision support system for hospitalized patients with type 2 diabetes on different wards. Diabetes Technol Ther. 2015;17(10):685–92.
pubmed: 26355756 pmcid: 4575539 doi: 10.1089/dia.2015.0027
Donsa K, Beck P, Holl B, Mader JK, Schaupp L, Plank J, et al. Impact of errors in paper-based and computerized diabetes management with decision support for hospitalized patients with type 2 diabetes. A post-hoc analysis of a before and after study. Int J Med Inform. 2016;90:58–67.
pubmed: 27103198 doi: 10.1016/j.ijmedinf.2016.03.007

Auteurs

Julia K Mader (JK)

Klinische Abteilung für Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich. julia.mader@medunigraz.at.

Johanna M Brix (JM)

Medizinische Abteilung mit Diabetologie, Endokrinologie und Nephrologie, Klinik Landstraße, Wien, Österreich.

Felix Aberer (F)

Klinische Abteilung für Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich.

Alexander Vonbank (A)

Innere Medizin I mit Kardiologie, Angiologie, Endokrinologie, Diabetologie und Intensivmedizin, Akademisches Lehrkrankenhaus Feldkirch, Feldkirch, Österreich.

Michael Resl (M)

Abteilung für Innere Medizin, Konventhospital der Barmherzigen Brüder Linz, Linz, Österreich.

Daniel A Hochfellner (DA)

Klinische Abteilung für Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich.

Claudia Ress (C)

Innere Medizin, Department I, Medizinische Universität Innsbruck, Innsbruck, Österreich.

Thomas R Pieber (TR)

Klinische Abteilung für Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich.

Lars Stechemesser (L)

Universitätsklinik für Innere Medizin I, Paracelsus Medizinische Privatuniversität - Landeskrankenhaus, Salzburg, Österreich.

Harald Sourij (H)

Klinische Abteilung für Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › [Hospital diabetes management (Update 2023)].
questionsmedicales.fr › Maladies endocriniennes › Diabète › [Hospital diabetes management (Update 2023)].
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › [Hospital diabetes management (Update 2023)].
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Hormones peptidiques › Hormones pancréatiques › Insulines › Insuline › [Hospital diabetes management (Update 2023)].
questionsmedicales.fr › Glucides › Sucres › Oses › Hexose › Glucose › Glycémie › [Hospital diabetes management (Update 2023)].
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Établissements de santé › Hôpitaux › [Hospital diabetes management (Update 2023)].
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › [Hospital diabetes management (Update 2023)].